The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
MS Treatments
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Ziemssen T, Groth M, Ettle B, Bopp T.
Verlag
Publisher-Information
Hum Vaccin Immunother. 2024 Dec 31;20(1):2316422.
Link
Zur Publikation (externer Server)
https://doi.org/10.1080/21645515.2024.2316422
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Neuroimmunologie
Treatments
MSZ
NIL
2024
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab
MS Treatments
Jahr
2024
Sensitive Identification of Asymmetries and Neuromuscular Deficits in Lower Limb Function in Early Multiple Sclerosis
Mobility
Jahr
2024
Neurofilaments as biomarkers in neurological disorders — towards clinical application
NIL
Jahr
2024
Use of machine learning algorithms to detect fear of falling in people with multiple sclerosis
Mobility
Jahr
2024
Consensus quality indicators for monitoring multiple sclerosis
MASC
Jahr
2024
